Published • loading... • Updated
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
MediLink granted Roche exclusive rights to develop and commercialize YL201 globally except China, with $570 million upfront and milestone payments to accelerate global approvals.
- On Jan. 8, 2026 in Suzhou, MediLink Therapeutics announced it granted Roche an exclusive license to develop, manufacture and commercialize YL201 worldwide excluding mainland China, Hong Kong SAR and Macau.
- Building on a January 2024 tie-up, the companies said the agreement leverages complementary strengths to speed YL201 toward global regulatory approvals and deepens joint development ties for the YL211 program.
- Financial terms include US$ 570 million upfront and near-term payments plus milestones and royalties; YL201 earned FDA Breakthrough Therapy designation in June 2025 and Orphan Drug designations for SCLC, NPC and ESCC.
- YL201 is currently being studied in multinational trials for multiple advanced solid tumors, with preliminary data showing promising response rates and survival benefits in second-line small cell lung cancer patients.
- MediLink Therapeutics, with R&D subsidiaries in Shanghai, Boston and Singapore, leverages its TMALIN platform supporting three clinical-stage ADC candidates to support YL201's global development.
Insights by Ground AI
31 Articles
31 Articles
MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
SUZHOU, China, Jan. 8, 2026 /PRNewswire/ -- MediLink Therapeutics ("MediLink") today announced that it has entered into a new collaboration and exclusive licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and commercialization of YL201, an investigational…
Roche returns to Chinese biotech MediLink for another ADC pact
Roche has signed another licensing deal with its China-based partner MediLink, this time focused on an antibody-drug conjugate for solid tumors that targets B7-H3. The Swiss drugmaker will obtain exclusive rights to MediLink’s drug, called ...
Coverage Details
Total News Sources31
Leaning Left4Leaning Right4Center17Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
L 16%
C 68%
R 16%
Factuality
To view factuality data please Upgrade to Premium
